Trump Imposes New Tariffs on Drone Imports Over US Security Concerns 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
US Dollar Slips as Softer PPI Data Eases Fed Rate Hike Expectations 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Asian Stocks Rise as AI Chip Rally Lifts South Korea, Japan 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
KOSPI Eyes Best Weekly Gain Since June as Samsung, SK Hynix Rally 
Gold Prices Slip From Two-Month High as Inflation and Fed Outlook Drive Markets 
European Stocks Rise as U.S. Inflation Data Eases Fed Rate Hike Fears 
3 clinical-grade skincare creams you really shouldn’t buy online 
KOSPI Rebounds 20% as Samsung, SK Hynix Lead South Korea Stock Rally 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Add as a preferred source on Google
A South Korean research team has developed a strip-type urine test that successfully diagnoses prostate and pancreatic cancer on-site by amplifying the optical signal of the metabolome in urine.
The joint research team is from the Korea Institute of Materials Science, Pohang University of Science and Technology, and Kyung Hee University
The surface-enhanced Raman scattering sensor that they developed can amplify the optical signal of the metabolome in urine by more than 1 billion times by forming a coral reef-shaped plasmonic nanomaterial on top of porous paper material.
A light irradiation after a 10-microliter urine droplet amplified signal of cancer metabolome on the sensor’s surface without the need to go through a separate analysis process,.
The application of an artificial intelligence-based analytical method for the spectrum signal generated through the irradiation of light into the urine can identify people with prostate cancer and pancreatic cancer with an accuracy of up to 99 percent.
